140 related articles for article (PubMed ID: 16446498)
1. Resibufogenin corrects hypertension in a rat model of human preeclampsia.
Vu H; Ianosi-Irimie M; Danchuk S; Rabon E; Nogawa T; Kamano Y; Pettit GR; Wiese T; Puschett JB
Exp Biol Med (Maywood); 2006 Feb; 231(2):215-20. PubMed ID: 16446498
[TBL] [Abstract][Full Text] [Related]
2. Marinobufagenin, resibufogenin and preeclampsia.
Puschett JB; Agunanne E; Uddin MN
Biochim Biophys Acta; 2010 Dec; 1802(12):1246-53. PubMed ID: 20167272
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension.
Fedorova OV; Simbirtsev AS; Kolodkin NI; Kotov AY; Agalakova NI; Kashkin VA; Tapilskaya NI; Bzhelyansky A; Reznik VA; Frolova EV; Nikitina ER; Budny GV; Longo DL; Lakatta EG; Bagrov AY
J Hypertens; 2008 Dec; 26(12):2414-25. PubMed ID: 19008721
[TBL] [Abstract][Full Text] [Related]
4. Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome.
Horvat D; Severson J; Uddin MN; Mitchell B; Puschett JB
Hypertens Pregnancy; 2010 Jan; 29(1):1-9. PubMed ID: 19277924
[TBL] [Abstract][Full Text] [Related]
5. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
Fedorova OV; Kolodkin NI; Agalakova NI; Lakatta EG; Bagrov AY
Hypertension; 2001 Feb; 37(2 Pt 2):462-6. PubMed ID: 11230319
[TBL] [Abstract][Full Text] [Related]
6. Involvement of marinobufagenin in a rat model of human preeclampsia.
Vu HV; Ianosi-Irimie MR; Pridjian CA; Whitbred JM; Durst JM; Bagrov AY; Fedorova OV; Pridjian G; Puschett JB
Am J Nephrol; 2005; 25(5):520-8. PubMed ID: 16179779
[TBL] [Abstract][Full Text] [Related]
7. Resibufogenin administration prevents oxidative stress in a rat model of human preeclampsia.
Uddin MN; Agunanne EE; Horvat D; Puschett JB
Hypertens Pregnancy; 2012; 31(1):70-8. PubMed ID: 21174582
[TBL] [Abstract][Full Text] [Related]
8. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia.
Lopatin DA; Ailamazian EK; Dmitrieva RI; Shpen VM; Fedorova OV; Doris PA; Bagrov AY
J Hypertens; 1999 Aug; 17(8):1179-87. PubMed ID: 10466474
[TBL] [Abstract][Full Text] [Related]
9. Antibody against Na/K-ATPase Inhibitor Lowers Blood Pressure and Increases Vascular Fli1 in Experimental Preeclampsia.
Agalakova NI; Reznik VA; Nadei OV; Ershov IA; Rassokha OS; Vasyutina ML; Ivanov DO; Adair CD; Galagudza MM; Bagrov AY
Am J Hypertens; 2020 May; 33(6):514-519. PubMed ID: 31713584
[TBL] [Abstract][Full Text] [Related]
10. Leptin-induced increase in blood pressure and markers of endothelial activation during pregnancy in Sprague Dawley rats is prevented by resibufogenin, a marinobufagenin antagonist.
Hassan MJM; Bakar NS; Aziz MA; Basah NK; Singh HJ
Reprod Biol; 2020 Jun; 20(2):184-190. PubMed ID: 32253169
[TBL] [Abstract][Full Text] [Related]
11. Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension.
Fedorova OV; Talan MI; Agalakova NI; Lakatta EG; Bagrov AY
Circulation; 2002 Mar; 105(9):1122-7. PubMed ID: 11877366
[TBL] [Abstract][Full Text] [Related]
12. Marinobufagenin predicts and resibufogenin prevents preeclampsia: a review of the evidence.
Puschett JB
Am J Perinatol; 2012 Nov; 29(10):777-85. PubMed ID: 22814872
[TBL] [Abstract][Full Text] [Related]
13. Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia.
Fedorova OV; Ishkaraeva VV; Grigorova YN; Reznik VA; Kolodkin NI; Zazerskaya IE; Zernetkina V; Agalakova NI; Tapilskaya NI; Adair CD; Lakatta EG; Bagrov AY
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30104471
[TBL] [Abstract][Full Text] [Related]
14. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.
Fedorova OV; Talan MI; Agalakova NI; Droy-Lefaix MT; Lakatta EG; Bagrov AY
Hypertension; 2003 Mar; 41(3):505-11. PubMed ID: 12623951
[TBL] [Abstract][Full Text] [Related]
15. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats.
Fedorova OV; Lakatta EG; Bagrov AY
Circulation; 2000 Dec; 102(24):3009-14. PubMed ID: 11113054
[TBL] [Abstract][Full Text] [Related]
16. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives.
Anderson DE; Fedorova OV; Morrell CH; Longo DL; Kashkin VA; Metzler JD; Bagrov AY; Lakatta EG
Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1248-54. PubMed ID: 18287222
[TBL] [Abstract][Full Text] [Related]
17. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia.
Averina IV; Tapilskaya NI; Reznik VA; Frolova EV; Fedorova OV; Lakatta EG; Bagrov AY
Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(8):19-23. PubMed ID: 17535731
[TBL] [Abstract][Full Text] [Related]
18. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.
Bagrov AY; Shapiro JI; Fedorova OV
Pharmacol Rev; 2009 Mar; 61(1):9-38. PubMed ID: 19325075
[TBL] [Abstract][Full Text] [Related]
19. Effects of resibufogenin in experimental hypertension.
Danchuk S; Sukhanov S; Horvat D; Uddin MN; Puschett JB
Am J Nephrol; 2008; 28(1):8-13. PubMed ID: 17890853
[TBL] [Abstract][Full Text] [Related]
20. Binding of ouabain and marinobufagenin leads to different structural changes in Na,K-ATPase and depends on the enzyme conformation.
Klimanova EA; Petrushanko IY; Mitkevich VA; Anashkina AA; Orlov SN; Makarov AA; Lopina OD
FEBS Lett; 2015 Sep; 589(19 Pt B):2668-74. PubMed ID: 26297827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
